Physician profile

Scott N Schwendiman

Family Medicine · Boise, ID

NPI 1538110234

$1,671.56

in general payments reported to CMS, 2019-2025

32 companies · $808 in 2025

The $808 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).

See the full distribution for Family Medicine

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,169.63
Education$45.00
Consulting Fee$20.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $395.68 2019-2025 Farxiga, Breztri, Airsupra
Pfizer INC. $201.47 2019-2025
Novo Nordisk INC $184.30 2019-2025 Ozempic, Rybelsus, Wegovy
Lilly USA, LLC $117.33 2024-2025 Mounjaro, Zepbound
Amgen INC. $94.22 2019-2024 Evenity, Prolia
Stryker Corporation $79.38 2024-2025 Blueprint Patient Specific Instrumentation, Mako, Triathlon
Astellas Pharma US INC $57.86 2019-2025 Veozah
Exact Sciences Corporation $57.18 2024-2025 Cologuard Collection Kit, The Cologuard Plus Collection Kit
Corium, LLC $34.89 2025 Azstarys
Corcept Therapeutics $32.89 2024-2025 Korlym
Merck Sharp & Dohme LLC $32.45 2019-2020
Abbvie INC. $31.58 2025
Glaxosmithkline, LLC. $30.25 2023-2024 Arexvy, Trelegy Ellipta
Vertex Pharmaceuticals Incorporated $26.97 2025
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $23.33 2019
Show all 32 companies
CompanyGeneral paymentsYearsTop products
Axsome Therapeutics, INC. $21.84 2025 Symbravo
Novartis Pharmaceuticals Corporation $20.08 2025
Bayer Healthcare Pharmaceuticals INC. $20.00 2024
Alnylam Pharmaceuticals INC. $19.78 2024 Amvuttra
Sanofi Pasteur INC. $18.79 2023
Recor Medical INC $18.64 2024 Paradise Renal Denervation System
Dexcom, INC. $18.04 2024 Dexcom G6 Transmitter
Exeltis, USA INC. $17.80 2025 Slynd
Phathom Pharmaceuticals, INC. $17.22 2025 Voquezna
Amarin Pharma, INC. $16.75 2020
Viatris Specialty LLC $14.83 2025 Yupelri
Shield Therapeutics INC $14.62 2024
Takeda Pharmaceuticals U.S.A., INC. $13.65 2019
Teva Pharmaceuticals USA, INC. $12.02 2019
Sonex Health, INC. $11.13 2025 Sx-One Microknife
Ultragenyx Pharmaceutical INC. $10.54 2019
Mayne Pharma Commercial LLC $6.05 2025

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Scott N Schwendiman

$1,671.56

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $808 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/463828/scott-n-schwendiman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.